Does Macrobid Cover Strep?
No, Macrobid (nitrofurantoin) does not adequately cover streptococcal infections and should not be used for this purpose.
FDA-Approved Indications
Macrobid is FDA-approved only for acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus 1. Notably absent from this indication is any streptococcal species, including Group A Streptococcus or Group B Streptococcus (Streptococcus agalactiae).
Spectrum of Activity Against Streptococcus
The antimicrobial spectrum of nitrofurantoin is narrow and specifically targets E. coli and S. saprophyticus 2. The FDA label explicitly states that nitrofurantoin "lacks the broader tissue distribution of other therapeutic agents" and is not indicated for infections requiring systemic tissue penetration 1.
Research Evidence on Strep Coverage
Limited older research from 1982 examined nitrofurantoin's activity against Streptococcus agalactiae (Group B Strep) and found:
- Minimum inhibitory concentrations (MIC) ranged from 8 to >64 mg/L 3
- These MIC values are considerably higher than for beta-lactam antibiotics like amoxicillin (0.03-0.5 mg/L) 3
- This indicates poor intrinsic activity against streptococcal species
Clinical Implications
Nitrofurantoin achieves high concentrations only in urine, with minimal serum and tissue levels 4. This pharmacokinetic profile means:
- It cannot treat systemic streptococcal infections (pharyngitis, skin infections, bacteremia)
- Even for streptococcal UTIs, it would be suboptimal given the poor MIC data
- Beta-lactam antibiotics (penicillins, cephalosporins) remain the drugs of choice for streptococcal infections 3
Common Pitfall to Avoid
Do not assume that because nitrofurantoin is a first-line UTI agent 5, 2, it covers all urinary pathogens. Its spectrum is intentionally narrow to minimize collateral damage to normal flora 2, 4. If a patient has a UTI with Group B Streptococcus or other streptococcal species identified on culture, switch to a beta-lactam antibiotic rather than continuing nitrofurantoin 1.